isTab: true
Zurück
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2004
Vor

Influence of female sex and fertile age on neuromyelitis optica spectrum disorders
Borisow N, Kleiter I, Gahlen A, Fischer K, Wernecke K, Pache F, Ruprecht K, Havla J, Krumbholz M, Kümpfel T, Aktas O, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Weissert R, Stellmann J, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Winkelmann A, Marouf W, Rückriem L, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Hellwig K
MULT SCLER J. 2017;23(8):1092-1103.

Glucocorticoid receptor in T cells mediates protection from autoimmunity in pregnancy
Engler J, Kursawe N, Solano M, Patas K, Wehrmann S, Heckmann N, Lühder F, Reichardt H, Arck P, Gold S, Friese M
P NATL ACAD SCI USA. 2017;114(2):E181-E190.

Numeracy of multiple sclerosis patients
Gaissmaier W, Giese H, Galesic M, Garcia-Retamero R, Kasper J, Kleiter I, Meuth S, Köpke S, Heesen C
PATIENT EDUC COUNS. 2017 [Epub ahead of print].

Control conditions for randomised trials of behavioural interventions in psychiatry: a decision framework
Gold S, Enck P, Hasselmann H, Friede T, Hegerl U, Mohr D, Otte C
LANCET PSYCHIAT. 2017 [Epub ahead of print].

Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients
Heesen C, Kleiter I, Meuth S, Krämer J, Kasper J, Köpke S, Gaissmaier W
J NEUROL SCI. 2017;376:181-190.

Therapie der primär und sekundär chronisch-progredienten MS
Hodecker S, Friese M
Der Neurologe & Psychiater : DNP. 2017;18(4):30-38.

Ruxolitinib treatment in a patient with neuromyelitis optica: A case report
Hodecker S, Stellmann J, Rosenkranz S, Young K, Holst B, Friese M, Heesen C
Neurol Neuroimmunol Neuroinflamm. 2017;4(2):e328.

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS
Hodecker S, Stürner K, Becker V, Elias-Hamp B, Holst B, Friese M, Heesen C
Neurol Neuroimmunol Neuroinflamm. 2017;4(2):e325.

Training doctors briefly and in situ to involve their patients in making medical decisions-Preliminary testing of a newly developed module
Kasper J, Liethmann K, Heesen C, Reissmann D, Geiger F
HEALTH EXPECT. 2017 [Epub ahead of print].

A new graphical format to communicate treatment effects to patients: A web-based randomized controlled trial
Kasper J, van de Roemer A, Pöttgen J, Rahn A, Backhus I, Bay Y, Köpke S, Heesen C
HEALTH EXPECT. 2017;20(4):797-804.

Can resistance training impact MRI outcomes in relapsing-remitting multiple sclerosis?
Kjølhede T, Siemonsen S, Wenzel D, Stellmann J, Ringgaard S, Pedersen B, Stenager E, Petersen T, Vissing K, Heesen C, Dalgas U
MULT SCLER J. 2017 [Epub ahead of print];1352458517722645.

Patient education programme on immunotherapy in multiple sclerosis (PEPIMS): A controlled rater-blinded study
Köpke S, Kasper J, Flachenecker P, Meißner H, Brandt A, Hauptmann B, Bender G, Backhus I, Rahn A, Pöttgen J, Vettorazzi E, Heesen C
CLIN REHABIL. 2017;31(2):250-261.

Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?
Krämer J, Tenberge J, Kleiter I, Gaissmaier W, Ruck T, Heesen C, Meuth S
PLOS ONE. 2017;12(4):e0174858.

Reduced rich-club connectivity is related to disability in primary progressive MS
Stellmann J, Hodecker S, Cheng B, Wanke N, Young K, Hilgetag C, Gerloff C, Heesen C, Thomalla G, Siemonsen S
Neurol Neuroimmunol Neuroinflamm. 2017;4(5):e375.

No relevant impact of ambient temperature on disability measurements in a large cohort of patients with multiple sclerosis
Stellmann J, Young K, Vettorazzi E, Pöttgen J, Heesen C
EUR J NEUROL. 2017;24(6):851-857.

T1 Recovery Is Predominantly Found in Black Holes and Is Associated with Clinical Improvement in Patients with Multiple Sclerosis
Thaler C, Faizy T, Sedlacik J, Holst B, Stürner K, Heesen C, Stellmann J, Fiehler J, Siemonsen S
AM J NEURORADIOL. 2017;38(2):264-269.

Patient education for people with multiple sclerosis-associated fatigue: A systematic review
Wendebourg M, Heesen C, Finlayson M, Meyer B, Pöttgen J, Köpke S
PLOS ONE. 2017;12(3):e0173025.

Brain activity, regional gray matter loss, and decision-making in multiple sclerosis
Weygandt M, Wakonig K, Behrens J, Meyer-Arndt L, Söder E, Brandt A, Bellmann-Strobl J, Ruprecht K, Gold S, Haynes J, Paul F
MULT SCLER J. 2017 [Epub ahead of print];1352458517717089.

Mesenchymal Stromal/Stem Cells Do Not Ameliorate Experimental Autoimmune Encephalomyelitis and Are Not Detectable in the Central Nervous System of Transplanted Mice
Abramowski P, Krasemann S, Ernst T, Lange C, Ittrich H, Schweizer M, Zander A, Martin R, Fehse B
STEM CELLS DEV. 2016;25(15):1134-48.

Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation
Andlauer T, Buck D, Antony G, Bayas A, Bechmann L, Berthele A, Chan A, Gasperi C, Gold R, Graetz C, Haas J, Hecker M, Infante-Duarte C, Knop M, Kümpfel T, Limmroth V, Linker R, Loleit V, Luessi F, Meuth S, Mühlau M, Nischwitz S, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann J, Stürner K, Tackenberg B, Then Bergh F, Tumani H, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl U, Ziemann U, Zipp F, Arloth J, Weber P, Radivojkov-Blagojevic M, Scheinhardt M, Dankowski T, Bettecken T, Lichtner P, Czamara D, Carrillo-Roa T, Binder E, Berger K, Bertram L, Franke A, Gieger C, Herms S, Homuth G, Ising M, Jöckel K, Kacprowski T, Kloiber S, Laudes M, Lieb W, Lill C, Lucae S, Meitinger T, Moebus S, Müller-Nurasyid M, Nöthen M, Petersmann A, Rawal R, Schminke U, Strauch K, Völzke H, Waldenberger M, Wellmann J, Porcu E, Mulas A, Pitzalis M, Sidore C, Zara I, Cucca F, Zoledziewska M, Ziegler A, Hemmer B, Müller-Myhsok B
SCI ADV. 2016;2(6):e1501678.

Effects of exercise on Irisin, BDNF and IL-6 serum levels in patients with progressive multiple sclerosis
Briken S, Rosenkranz S, Keminer O, Patra S, Ketels G, Heesen C, Hellweg R, Pless O, Schulz K, Gold S
J NEUROIMMUNOL. 2016;299:53-58.

Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder
Chavarro V, Mealy M, Simpson A, Lacheta A, Pache F, Ruprecht K, Gold S, Paul F, Brandt A, Levy M
Neurol Neuroimmunol Neuroinflamm. 2016;3(6):e286.

Heterogeneity of Multiple Sclerosis Lesions in Multislice Myelin Water Imaging
Faizy T, Thaler C, Kumar D, Sedlacik J, Broocks G, Grosser M, Stellmann J, Heesen C, Fiehler J, Siemonsen S
PLOS ONE. 2016;11(3):e0151496.

Widespread synaptic loss in multiple sclerosis
Friese M
BRAIN. 2016;139(Pt 1):2-4.

Improved Lesion Detection by Using Axial T2-Weighted MRI with Full Spinal Cord Coverage in Multiple Sclerosis
Galler S, Stellmann J, Young K, Kutzner D, Heesen C, Fiehler J, Siemonsen S
AM J NEURORADIOL. 2016;37(5):963-9.

Mapping search terms to review goals is essential
Geiger F, Clayman M, Scholl I, Liethmann K, Kasper J
BMJ QUAL SAF. 2016;25(2):130.

Sex-related factors in multiple sclerosis.
Gold S, Arnon R, Miller A
2016. Translational Neuroimmunology in Multiple Sclerosis: From Disease Mechanisms to Clinical Applications.. 1. Aufl. Academic Press Inc., 83-95.

Psychoneuroimmunologie und Krebs
Gold S, Schulz K
2016. Handbuch Psychoonkologie. Mehnert A, Koch U (Hrsg.). 1. Aufl. Göttingen: Hogrefe Verlag, 373-383.

Pregnancy and multiple sclerosis: from molecular mechanisms to clinical application
Gold S, Voskuhl R
SEMIN IMMUNOPATHOL. 2016;38(6):709-718.

Characterizing the phenotype of multiple sclerosis-associated depression in comparison with idiopathic major depression
Hasselmann H, Bellmann-Strobl J, Ricken R, Oberwahrenbrock T, Rose M, Otte C, Adli M, Paul F, Brandt A, Finke C, Gold S
MULT SCLER J. 2016;22(11):1476-1484.

Distinct functionality of neutrophils in Multiple Sclerosis and Neuromyelitis Optica.
Hertwig L, Pache F, Romero-Suarez S, Stürner K, Borisow N, Behrens J, Bellmann-Strobel J, Seeger B, Asselborn N, Ruprecht K, Millward J, Infante-Duarte C, Paul F
MULT SCLER J. 2016;22(2):160-73.

Neuromyelitis optica: Evaluation of 871 attacks and 1153 treatment courses
Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke K, Wegner B, Hellwig K, Pache F, Ruprecht K, Havla J, Krumbholz M, Kümpfel T, Aktas O, Hartung H, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann J, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Bergh F, Hofstadt-van Oy U, Neuhaus O, Winkelmann A, Marouf W, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C
ANN NEUROL. 2016;79(2):206-16.

Plasticity of Th17 Cells in Autoimmune Kidney Diseases
Krebs C, Turner J, Paust H, Kapffer S, Koyro T, Krohn S, Ufer F, Friese M, Flavell R, Stockinger B, Steinmetz O, Stahl R, Huber S, Panzer U
J IMMUNOL. 2016;197(2):449-57.

Noise robust spatially regularized myelin water fraction mapping with the intrinsic B1-error correction based on the linearized version of the extended phase graph model
Kumar D, Siemonsen S, Heesen C, Fiehler J, Sedlacik J
J MAGN RESON IMAGING. 2016;43(4):800-17.

Major depressive disorder.
Otte C, Gold S, Penninx B, Pariante C, Etkin A, Fava M, Mohr D, Schatzberg A
Nat Rev Dis Primers. 2016;2:16065.

Comprehension of confidence intervals - development and piloting of patient information materials for people with multiple sclerosis: qualitative study and pilot randomised controlled trial
Rahn A, Backhus I, Fuest F, Riemann-Lorenz K, Köpke S, van de Roemer A, Mühlhauser I, Heesen C
BMC MED INFORM DECIS. 2016;16(1):122.

Sex effects on inflammatory and neurodegenerative processes in multiple sclerosis
Ramien C, Taenzer A, Lupu A, Heckmann N, Engler J, Patas K, Friese M, Gold S
NEUROSCI BIOBEHAV R. 2016;67:137-46.

Subjective and objective knowledge and decisional role preferences in cerebrovascular patients compared to controls
Riechel C, Alegiani A, Köpke S, Kasper J, Rosenkranz M, Thomalla G, Heesen C
PATIENT PREFER ADHER. 2016;10:1453-60.

Dietary Interventions in Multiple Sclerosis: Development and Pilot-Testing of an Evidence Based Patient Education Program
Riemann-Lorenz K, Eilers M, von Geldern G, Schulz K, Köpke S, Heesen C
PLOS ONE. 2016;11(10):e0165246.

Multiple sclerosis: Molecular mimicry of an antimyelin HLA class I restricted T-cell receptor
Rühl G, Niedl A, Patronov A, Siewert K, Pinkert S, Kalemanov M, Friese M, Attfield K, Antes I, Hohlfeld R, Dornmair K
Neurol Neuroimmunol Neuroinflamm. 2016;3(4):e241.

Activity of NaV1.2 promotes neurodegeneration in an animal model of multiple sclerosis
Schattling B, Fazeli W, Engeland B, Liu Y, Lerche H, Isbrandt D, Friese M
JCI Insight. 2016;1(19):e89810.

Pattern of gray matter volumes related to retinal thickness and its association with cognitive function in relapsing–remitting MS
Stellmann J, Cetin H, Young K, Hodecker S, Pöttgen J, Bittersohl D, Hassenstein A, Oberwahrenbrock T, Heesen C, Siemonsen S
BRAIN BEHAV. 2016;7(2):e00614.

Fampridine and real-life walking in multiple sclerosis: Low predictive value of clinical test for habitual short-term changes
Stellmann J, Jlussi M, Neuhaus A, Lederer C, Daumer M, Heesen C
J NEUROL SCI. 2016;368:318-25.

Arc/Arg3.1 governs inflammatory dendritic cell migration from the skin and thereby controls T cell activation
Ufer F, Vargas P, Engler J, Tintelnot J, Schattling B, Winkler H, Bauer S, Kursawe N, Willing A, Keminer O, Ohana O, Salinas-Riester G, Pless O, Kuhl D, Friese M
Sci Immunol. 2016;1(3):eaaf8665.

Short-term MRI measurements as predictors of EDSS progression in relapsing-remitting multiple sclerosis: grey matter atrophy but not lesions are predictive in a real-life setting
von Gumberz J, Mahmoudi M, Young K, Schippling S, Martin R, Heesen C, Siemonsen S, Stellmann J
PEERJ. 2016;4:e2442.

Development and Feasibility of an Evidence-Based Patient Education Program for Managing Fatigue in Multiple Sclerosis: The "Fatigue Management in MS" Program (FatiMa)
Wendebourg M, Feddersen L, Lau S, Köpke S, Moss-Morris R, Heesen C, Pöttgen J
Int J MS Care. 2016;18(3):129-37.

Stress-induced brain activity, brain atrophy, and clinical disability in multiple sclerosis
Weygandt M, Meyer-Arndt L, Behrens J, Wakonig K, Bellmann-Strobl J, Ritter K, Scheel M, Brandt A, Labadie C, Hetzer S, Gold S, Paul F, Haynes J
P NATL ACAD SCI USA. 2016;113(47):13444-449.

"History had taken such a large piece out of my life" - Neuroscientist refugees from Hamburg during National Socialism
Zeidman L, von Villiez A, Stellmann J, Bussche van den H
J HIST NEUROSCI. 2016;25(3):275-98.

Increased perfusion in normal appearing white matter in high inflammatory multiple sclerosis patients
Bester M, Forkert N, Stellmann J, Aly L, Drabik A, Young K, Heesen C, Fiehler J, Siemonsen S
PLOS ONE. 2015;10(3):e0119356.

Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array
Dankowski T, Buck D, Andlauer T, Antony G, Bayas A, Bechmann L, Berthele A, Bettecken T, Chan A, Franke A, Gold R, Graetz C, Haas J, Hecker M, Herms S, Infante-Duarte C, Jöckel K, Kieseier B, Knier B, Knop M, Kümpfel T, Lichtner P, Lieb W, Lill C, Limmroth V, Linker R, Loleit V, Meuth S, Moebus S, Müller-Myhsok B, Nischwitz S, Nöthen M, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann J, Strauch K, Stürner K, Tackenberg B, Then Bergh F, Tumani H, Waldenberger M, Weber F, Wiendl H, Wildemann B, Zettl U, Ziemann U, Zipp F, Hemmer B, Ziegler A
GENET EPIDEMIOL. 2015;39(8):601-8.

Patient expression of emotions and neurologist responses in first multiple sclerosis consultations
Del Piccolo L, Pietrolongo E, Radice D, Tortorella C, Confalonieri P, Pugliatti M, Lugaresi A, Giordano A, Heesen C, Solari A
PLOS ONE. 2015;10(6):e0127734.

Immunopathology of multiple sclerosis
Dendrou C, Fugger L, Friese M
NAT REV IMMUNOL. 2015;15(9):545-58.

Diagnostic accuracy for major depression in multiple sclerosis using self-report questionnaires
Fischer A, Fischer M, Nicholls R, Lau S, Poettgen J, Patas K, Heesen C, Gold S
BRAIN BEHAV. 2015;5(9):e00365.

Steroid regulation of T cell function appears unaltered in borderline personality disorder
Fischer A, Grundmann J, Gold S, Spitzer C, Wingenfeld K
J PERS DISORD. 2015;29(2):241-7.

An online programme to reduce depression in patients with multiple sclerosis: a randomised controlled trial.
Fischer A, Schröder J, Vettorazzi E, Wolf O, Pöttgen J, Lau S, Heesen C, Moritz S, Gold S
LANCET PSYCHIAT. 2015;2(3):217-223.

Relapse in multiple sclerosis
Galea I, Ward-Abel N, Heesen C
BMJ-BRIT MED J. 2015;350:h1765.

Changes of Motivational Variables in Patients with Multiple Sclerosis in an Exercise Intervention: Associations between Physical Performance and Motivational Determinants
Geertz W, Dechow A, Patra S, Heesen C, Gold S, Schulz K
BEHAV NEUROL. 2015;2015:248193.

Risk Knowledge in Relapsing Multiple Sclerosis (RIKNO 1.0)-Development of an Outcome Instrument for Educational Interventions
Heesen C, Kasper J, Fischer K, Köpke S, Rahn A, Backhus I, Poettgen J, Vahter L, Drulovic J, Van Nunen A, Beckmann Y, Liethmann K, Giordano A, Fulcher G, Solari A
PLOS ONE. 2015;10(10):e0138364.

Thalamic-hippocampal-prefrontal disruption in relapsing-remitting multiple sclerosis
Kern K, Gold S, Lee B, Montag M, Horsfall J, O'Connor M, Sicotte N
NEUROIMAGE-CLIN. 2015;8:440-7.

Complement C1q-C3-associated synaptic changes in multiple sclerosis hippocampus
Michailidou I, Willems J, Kooi E, van Eden C, Gold S, Geurts J, Baas F, Huitinga I, Ramaglia V
ANN NEUROL. 2015;77(6):1007-26.

Multiple sclerosis associated genetic variants of CD226 impair regulatory T cell function
Piedavent-Salomon M, Willing A, Engler J, Steinbach K, Bauer S, Eggert B, Ufer F, Kursawe N, Wehrmann S, Jäger J, Reinhardt S, Friese M
BRAIN. 2015;138(Pt 11):3263-74.

Central role of Th2/Tc2 lymphocytes in pattern II multiple sclerosis lesions
Planas R, Metz I, Ortiz Y, Vilarrasa N, Jelčić I, Salinas-Riester G, Heesen C, Brück W, Martin R, Sospedra M
Ann Clin Transl Neurol. 2015;2(9):875-93.

Managing Neuropsychological Impairment in Multiple Sclerosis: Pilot Study on a Standardized Metacognitive Intervention
Pöttgen J, Lau S, Penner I, Heesen C, Moritz S
Int J MS Care. 2015;17(3):130-7.

Evaluator-blinded trial evaluating nurse-led immunotherapy DEcision Coaching In persons with relapsing-remitting Multiple Sclerosis (DECIMS) and accompanying process evaluation: study protocol for a cluster randomised controlled trial
Rahn A, Köpke S, Kasper J, Vettorazzi E, Mühlhauser I, Heesen C
TRIALS. 2015;16(1):106.

Autoimmune Enzephalitiden-Assoziierte Antikörper sind entscheidene Marker für Pathogenese und Prognose
Rosenkranz S, Friese M
Info Neurol Psych. 2015;17(10):38-49.

Ecological validity of walking capacity tests in multiple sclerosis
Stellmann J, Neuhaus A, Götze I, Briken S, Lederer C, Schimpl M, Heesen C, Daumer M
PLOS ONE. 2015;10(4):e0123822.

Stammzelltransplantation bei Multipler Sklerose. Hamburger Erfahrungen und internationaler Forschungsstand
Stellmann J, Stürner K, Ufer F, Havemeister S, Pöttgen J, Ayuketang F, Kröger N, Friese M, Heesen C
NERVENARZT. 2015;86(8):989-96.

Regression to the mean and predictors of MRI disease activity in RRMS placebo cohorts--is there a place for baseline-to-treatment studies in MS?
Stellmann J, Stürner K, Young K, Siemonsen S, Friede T, Heesen C
PLOS ONE. 2015;10(2):e0116559.

Introducing a new method to assess vision: Computer-adaptive contrast-sensitivity testing predicts visual functioning better than charts in multiple sclerosis patients
Stellmann J, Young K, Pöttgen J, Dorr M, Heesen C
Mult Scler J-Exp Transl Clin. 2015;1(1):1-8.

T1- Thresholds in Black Holes Increase Clinical-Radiological Correlation in Multiple Sclerosis Patients
Thaler C, Faizy T, Sedlacik J, Holst B, Stellmann J, Young K, Heesen C, Fiehler J, Siemonsen S
PLOS ONE. 2015;10(12):e0144693.

Neurosarkoidose
Ufer F, Friese M
AKTUEL NEUROL. 2015;42(04):218-227.

Immune and neurotrophin stimulation by electroconvulsive therapy: is some inflammation needed after all?
van Buel E, Patas K, Peters M, Bosker F, Eisel U, Klein H
TRANSL PSYCHIAT. 2015;5:e609.

A truncation variant of the cation channel P2RX5 is upregulated during T cell activation
Abramowski P, Ogrodowczyk C, Martin R, Pongs O
PLOS ONE. 2014;9(9):e104692.

The orally available, synthetic ether lipid edelfosine inhibits T cell proliferation and induces a type I interferon response
Abramowski P, Otto B, Martin R
PLOS ONE. 2014;9(3):e91970.

Immunomodulatory effects of the ether phospholipid edelfosine in experimental autoimmune encephalomyelitis
Abramowski P, Steinbach K, Zander A, Martin R
J NEUROIMMUNOL. 2014;274(1-2):111-24.

Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMS-Trial
Borreani C, Giordano A, Falautano M, Lugaresi A, Martinelli V, Granella F, Tortorella C, Plasmati I, Radaelli M, Farina D, Dalla Bella E, Bianchi E, Acquarone N, Miccinesi G, Solari A, , Heesen C
HEALTH EXPECT. 2014;17(1):36-48.

Magnetic resonance imaging in multiple sclerosis--patients' experiences, information interests and responses to an education programme
Brand J, Köpke S, Kasper J, Rahn A, Backhus I, Poettgen J, Stellmann J, Siemonsen S, Heesen C
PLOS ONE. 2014;9(11):e113252.

Effects of exercise on fitness and cognition in progressive MS: a randomized, controlled pilot trial
Briken S, Gold S, Patra S, Vettorazzi E, Harbs D, Tallner A, Ketels G, Schulz K, Heesen C
MULT SCLER J. 2014;20(3):382-90.

Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis
Friese M, Schattling B, Fugger L
NAT REV NEUROL. 2014;10(4):225-38.

Transient receptor potential melastatin subfamily member 2 cation channel regulates detrimental immune cell invasion in ischemic stroke
Gelderblom M, Melzer N, Schattling B, Göb E, Hicking G, Arunachalam P, Bittner S, Ufer F, Herrmann A, Bernreuther C, Glatzel M, Gerloff C, Kleinschnitz C, Meuth S, Friese M, Magnus T
STROKE. 2014;45(11):3395-3402.

Detection of altered hippocampal morphology in multiple sclerosis-associated depression using automated surface mesh modeling
Gold S, O'Connor M, Gill R, Kern K, Shi Y, Henry R, Pelletier D, Mohr D, Sicotte N
HUM BRAIN MAPP. 2014;35(1):30-37.

Adherence in multiple sclerosis (ADAMS): classification, relevance, and research needs. A meeting report
Heesen C, Bruce J, Feys P, Sastre-Garriga J, Solari A, Eliasson L, Matthews V, Hausmann B, Ross A, Asano M, Imonen-Charalambous K, Köpke S, Clyne W, Bissell P
MULT SCLER J. 2014;20(13):1795-8.

Does the patient know best? Quality of life assessment in multiple sclerosis trials
Heesen C, Cohen J
MULT SCLER J. 2014;20(2):131-2.

Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial
Köpke S, Kern S, Ziemssen T, Berghoff M, Kleiter I, Marziniak M, Paul F, Vettorazzi E, Pöttgen J, Fischer K, Kasper J, Heesen C
J NEUROL NEUROSUR PS. 2014;85(4):411-8.

Information provision for people with multiple sclerosis
Köpke S, Solari A, Khan F, Heesen C, Giordano A
COCHRANE DB SYST REV. 2014;4:CD008757.

Immunological challenges for peptide-based immunotherapy in glioblastoma
Mohme M, Neidert M, Regli L, Weller M, Martin R
CANCER TREAT REV. 2014;40(2):248-58.

Association between serum brain-derived neurotrophic factor and plasma interleukin-6 in major depressive disorder with melancholic features
Patas K, Penninx B, Bus B, Vogelzangs N, Molendijk M, Elzinga B, Bosker F, Oude Voshaar R
BRAIN BEHAV IMMUN. 2014;36:71-9.

Acquired channelopathies as contributors to development and progression of multiple sclerosis
Schattling B, Eggert B, Friese M
EXP NEUROL. 2014;262 Pt A:28-36.

Efficacy of a psychological online intervention for depression in people with epilepsy: a randomized controlled trial
Schröder J, Brückner K, Fischer A, Lindenau M, Köther U, Vettorazzi E, Moritz S
EPILEPSIA. 2014;55(12):2069-2076.

A vaccine targeting mutant IDH1 induces antitumour immunity
Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, Menn O, Osswald M, Oezen I, Ott M, Keil M, Balß J, Rauschenbach K, Grabowska A, Vogler I, Diekmann J, Trautwein N, Eichmüller S, Okun J, Stevanović S, Riemer A, Sahin U, Friese M, Beckhove P, von Deimling A, Wick W, Platten M
NATURE. 2014;512(7514):324-7.

Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1
Sospedra M, Schippling S, Yousef S, Jelcic I, Bofill-Mas S, Planas R, Stellmann J, Demina V, Cinque P, Garcea R, Croughs T, Girones R, Martin R
CLIN INFECT DIS. 2014;59(11):1588-92.

Multiple Sklerose - Prädiktoren für Progression
Stellmann J, Heesen C
Neuroradiologie Scan. 2014;04(02):90-91.

Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review
Stellmann J, Neuhaus A, Lederer C, Daumer M, Heesen C
PLOS ONE. 2014;9(3):e92761.

A 3meter Timed Tandem Walk is an early marker of motor and cerebellar impairment in fully ambulatory MS patients
Stellmann J, Vettorazzi E, Poettgen J, Heesen C
J NEUROL SCI. 2014;346(1-2):99-106.

A multiple sclerosis-associated variant of CBLB links genetic risk with type I IFN function
Stürner K, Borgmeyer U, Schulze C, Pless O, Martin R
J IMMUNOL. 2014;193(9):4439-47.

Safety, tolerability and efficacy of Boswellic acids in relapsing-remitting multiple sclerosis - the SABA proof- of-concept trial
Stürner K, Stellmann J, Paul F, Dörr J, Martin R, Heesen C
MULT SCLER J. 2014;20:88-89.

Boswellic acids reduce Th17 differentiation via blockade of IL-1β-mediated IRAK1 signaling
Stürner K, Verse N, Yousef S, Martin R, Sospedra M
EUR J IMMUNOL. 2014;44(4):1200-1212.

Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)
Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, Borisow N, Kleiter I, Aktas O, Kümpfel T
J NEUROL. 2014;261(1):1-16.

CD8⁺ MAIT cells infiltrate into the CNS and alterations in their blood frequencies correlate with IL-18 serum levels in multiple sclerosis
Willing A, Leach O, Ufer F, Attfield K, Steinbach K, Kursawe N, Piedavent M, Friese M
EUR J IMMUNOL. 2014;44(10):3119-28.

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
Beecham A, Patsopoulos N, Xifara D, Davis M, Kemppinen A, Cotsapas C, Shah T, Spencer C, Booth D, Goris A, Oturai A, Saarela J, Fontaine B, Hemmer B, Martin C, Zipp F, D'Alfonso S, Martinelli-Boneschi F, Taylor B, Harbo H, Kockum I, Hillert J, Olsson T, Ban M, Oksenberg J, Hintzen R, Barcellos L, Agliardi C, Alfredsson L, Alizadeh M, Anderson C, Andrews R, Søndergaard H, Baker A, Band G, Baranzini S, Barizzone N, Barrett J, Bellenguez C, Bergamaschi L, Bernardinelli L, Berthele A, Biberacher V, Binder T, Blackburn H, Bomfim I, Brambilla P, Broadley S, Brochet B, Brundin L, Buck D, Butzkueven H, Caillier S, Camu W, Carpentier W, Cavalla P, Celius E, Coman I, Comi G, Corrado L, Cosemans L, Cournu-Rebeix I, Cree B, Cusi D, Damotte V, Defer G, Delgado S, Deloukas P, di Sapio A, Dilthey A, Donnelly P, Dubois B, Duddy M, Edkins S, Elovaara I, Esposito F, Evangelou N, Fiddes B, Field J, Franke A, Freeman C, Frohlich I, Galimberti D, Gieger C, Gourraud P, Graetz C, Graham A, Grummel V, Guaschino C, Hadjixenofontos A, Hakonarson H, Halfpenny C, Hall G, Hall P, Hamsten A, Harley J, Harrower T, Hawkins C, Hellenthal G, Hillier C, Hobart J, Hoshi M, Hunt S, Jagodic M, Jelcic I, Jochim A, Kendall B, Kermode A, Kilpatrick T, Koivisto K, Konidari I, Korn T, Kronsbein H, Langford C, Larsson M, Lathrop M, Lebrun-Frenay C, Lechner-Scott J, Lee M, Leone M, Leppä V, Liberatore G, Lie B, Lill C, Lindén M, Link J, Luessi F, Lycke J, Macciardi F, Männistö S, Manrique C, Martin R, Martinelli V, Mason D, Mazibrada G, McCabe C, Mero I, Mescheriakova J, Moutsianas L, Myhr K, Nagels G, Nicholas R, Nilsson P, Piehl F, Pirinen M, Price S, Quach H, Reunanen M, Robberecht W, Robertson N, Rodegher M, Rog D, Salvetti M, Schnetz-Boutaud N, Sellebjerg F, Selter R, Schaefer C, Shaunak S, Shen L, Shields S, Siffrin V, Slee M, Sorensen P, Sorosina M, Sospedra M, Spurkland A, Strange A, Sundqvist E, Thijs V, Thorpe J, Ticca A, Tienari P, van Duijn C, Visser E, Vucic S, Westerlind H, Wiley J, Wilkins A, Wilson J, Winkelmann J, Zajicek J, Zindler E, Haines J, Pericak-Vance M, Ivinson A, Stewart G, Hafler D, Hauser S, Compston A, McVean G, De Jager P, Sawcer S, McCauley J
NAT GENET. 2013;45(11):1353-60.

An evidence-based shared decision making programme on the prevention of myocardial infarction in type 2 Diabetes: protocol of a randomised-controlled trial
Buhse S, Heller T, Kasper J, Mühlhauser I, Müller U, Lehmann T, Lenz M
BMC FAM PRACT. 2013;14:155.

A clinical and neurobiological case of IgM NMDA receptor antibody associated encephalitis mimicking bipolar disorder.
Choe C, Karamatskos E, Schattling B, Leypoldt F, Liuzzi G, Gerloff C, Friese M, Mulert C
PSYCHIAT RES. 2013;208(2):194-196.

Adhesion molecule L1 binds to amyloid beta and reduces Alzheimer's disease pathology in mice.
Djogo N, Jakovcevski I, Müller C, Lee H, Xu J, Jakovcevski M, Kügler S, Loers G, Schachner M
NEUROBIOL DIS. 2013;56:104-115.

Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage
Filippi M, Rocca M, Pagani E, De Stefano N, Jeffery D, Kappos L, Montalban X, Boyko A, Comi G
J NEUROL NEUROSUR PS. 2013.

Enzephalopathien bei Infektionserkrankungen
Friese M, Gerloff C, Weber T
2013. Bewusstseinsstörungen und Enzephalopathien. Hansen H (Hrsg.). 1. Aufl. Berlin, Heidelberg: Springer, 327-339.

A web-based tool for personalized prediction of long-term disease course in patients with multiple sclerosis
Galea I, Lederer C, Neuhaus A, Muraro P, Scalfari A, Koch-Henriksen N, Heesen C, Koepke S, Stellmann J, Albrecht H, Winkelmann A, Weber F, Bahn E, Hauser M, Edan G, Ebers G, Daumer M
EUR J NEUROL. 2013;20(7):1107-9.

Plasma levels of neuron specific enolase quantify the extent of neuronal injury in murine models of ischemic stroke and multiple sclerosis
Gelderblom M, Daehn T, Schattling B, Ludewig P, Bernreuther C, Arunachalam P, Matschke J, Glatzel M, Gerloff C, Friese M, Magnus T
NEUROBIOL DIS. 2013;59:177-82.

Prognostic risk estimates of patients with multiple sclerosis and their physicians: comparison to an online analytical risk counseling tool
Heesen C, Gaissmaier W, Nguyen F, Stellmann J, Kasper J, Köpke S, Lederer C, Neuhaus A, Daumer M
PLOS ONE. 2013;8(5):e59042.

Patient autonomy in multiple sclerosis--possible goals and assessment strategies
Heesen C, Köpke S, Solari A, Geiger F, Kasper J
J NEUROL SCI. 2013;331(1-2):2-9.

Depressive syndromes in neurological disorders
Hellmann-Regen J, Piber D, Hinkelmann K, Gold S, Heesen C, Spitzer C, Endres M, Otte C
EUR ARCH PSY CLIN N. 2013;263 Suppl 2:S123-36.

Association between cortisol awakening response and memory function in major depression
Hinkelmann K, Muhtz C, Dettenborn-Betz L, Agorastos A, Moritz S, Wingenfeld K, Spitzer C, Gold S, Wiedemann K, Otte C
PSYCHOL MED. 2013;43(11):2255-63.

Long-term treatment risks in multiple sclerosis: risk knowledge and risk perception in a large cohort of mitoxantrone-treated patients
Hofmann A, Stellmann J, Kasper J, Ufer F, Elias W, Pauly I, Repenthin J, Rosenkranz T, Weber T, Köpke S, Heesen C
MULT SCLER J. 2013;19(7):920-925.

IL7RA haplotype-associated alterations in cellular immune function and gene expression patterns in multiple sclerosis
Jäger J, Schulze C, Rösner S, Martin R
GENES IMMUN . 2013;14(7):453-61.

T cell epitope mapping of JC polyoma virus-encoded proteome reveals reduced T cell responses in HLA-DRB1*04:01+ donors.
Jelcic I, Aly L, Binder T, Jelcic I, Bofill-Mas S, Planas R, Demina V, Eiermann T, Weber T, Girones R, Sospedra M, Martin R
J VIROL. 2013;87(6):3393-3408.

Recovery from severe frontotemporal dysfunction at 3years after N-methyl-d-aspartic acid (NMDA) receptor antibody encephalitis.
Leypoldt F, Gelderblom M, Schöttle D, Hoffmann S, Wandinger K
J CLIN NEUROSCI. 2013;20(4):611-613.

Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis
Lutterotti A, Yousef S, Sputtek A, Stürner K, Stellmann J, Breiden P, Reinhardt S, Schulze C, Bester M, Heesen C, Schippling S, Miller S, Sospedra M, Martin R
SCI TRANSL MED. 2013;5(188):188ra75.

HLA-DR15-derived self-peptides are involved in increased autologous T cell proliferation in multiple sclerosis.
Mohme M, Hotz C, Stevanovic S, Binder T, Lee J, Okoniewski M, Eiermann T, Sospedra M, Rammensee H, Martin R
BRAIN. 2013;136(Pt 6):1783-1798.

Myositis facilitates preclinical accumulation of pathological prion protein in muscle
Neumann M, Krasemann S, Schröck K, Steinbach K, Glatzel M
Acta Neuropathol Comm. 2013;1(1):78.

Pregnancy and multiple sclerosis: feto-maternal immune cross talk and its implications for disease activity
Patas K, Engler J, Friese M, Gold S
J REPROD IMMUNOL. 2013;97(1):140-6.

Decision-making in multiple sclerosis consultations in Italy: third observer and patient assessments
Pietrolongo E, Giordano A, Kleinefeld M, Confalonieri P, Lugaresi A, Tortorella C, Pugliatti M, Radice D, Goss C, Heesen C, Solari A
PLOS ONE. 2013;8(4):e60721.

Impaired social cognition in multiple sclerosis
Pöttgen J, Dziobek I, Reh S, Heesen C, Gold S
J NEUROL NEUROSUR PS. 2013;84(5):523-8.

Comparison of patient-reported outcome measures in multiple sclerosis
Schäffler N, Schönberg P, Stephan J, Stellmann J, Gold S, Heesen C
ACTA NEUROL SCAND. 2013;128(2):114-21.

Role Preferences of People with Multiple Sclerosis: Image-Revised, Computerized Self-Administered Version of the Control Preference Scale
Solari A, Giordano A, Kasper J, Drulovic J, van Nunen A, Vahter L, Viala F, Pietrolongo E, Pugliatti M, Antozzi C, Radice D, Köpke S, Heesen C
PLOS ONE. 2013;8(6):e66127.

Neutrophils amplify autoimmune central nervous system infiltrates by maturing local APCs
Steinbach K, Piedavent M, Bauer S, Neumann J, Friese M
J IMMUNOL. 2013;191(9):4531-9.

Loss of retinal nerve fibre layer axons indicates white but not grey matter damage in early multiple sclerosis
Young K, Brandt A, Petzold A, Reitz L, Lintze F, Paul F, Martin R, Schippling S
EUR J NEUROL. 2013;20(5):803-11.

Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations
Zimmermann H, Freing A, Kaufhold F, Gaede G, Bohn E, Bock M, Oberwahrenbrock T, Young K, Dörr J, Wuerfel J, Schippling S, Paul F, Brandt A
MULT SCLER J. 2013;19(4):443-50.

Decreased hydrocortisone sensitivity of T cell function in multiple sclerosis-associated major depression.
Fischer A, Otte C, Krieger T, Nicholls R, Krüger S, Ziegler K, Schulz K, Heesen C, Gold S
PSYCHONEUROENDOCRINO. 2012;37(10):1712-1718.

Of blind men and elephants: suggesting SDM-MASS as a compound measure for shared decision making integrating patient, physician and observer views.
Geiger F, Kasper J
ZEFQ Z Evidenz Fortbild Qual G. 2012;106(4):284-289.

Dynamic development of glucocorticoid resistance during autoimmune neuroinflammation.
Gold S, Sasidhar M, Lagishetty V, Spence R, Umeda E, Ziehn M, Krieger T, Schulz K, Heesen C, Hewison M, Voskuhl R
J CLIN ENDOCR METAB. 2012;97(8):1402-1410.

Don't stress about it! Is stress management a disease-modifying therapy for multiple sclerosis?
Heesen C, Gold S
NEUROLOGY. 2012;79(5):398-399.

Behavioral interventions in multiple sclerosis: a biopsychosocial perspective.
Heesen C, Köpke S, Kasper J, Poettgen J, Tallner A, Mohr D, Gold S
Expert Rev Neurother. 2012;12(9):1089-1100.

Completing the third person's perspective on patients' involvement in medical decision-making: approaching the full picture.
Kasper J, Hoffmann F, Heesen C, Köpke S, Geiger F
ZEFQ Z Evidenz Fortbild Qual G. 2012;106(4):275-283.

MAPPIN'SDM--the multifocal approach to sharing in shared decision making.
Kasper J, Hoffmann F, Heesen C, Köpke S, Geiger F
PLOS ONE. 2012;7(4):34849.

Applying the theory of planned behaviour to multiple sclerosis patients' decisions on disease modifying therapy--questionnaire concept and validation.
Kasper J, Köpke S, Fischer K, Schäffler N, Backhus I, Solari A, Heesen C
BMC MED INFORM DECIS. 2012;12:60.

Turning signals into meaning--'shared decision making' meets communication theory.
Kasper J, Légaré F, Scheibler F, Geiger F
HEALTH EXPECT. 2012;15(1):3-11.

Implementation of a patient education program on multiple sclerosis relapse management.
Köpke S, Richter T, Kasper J, Mühlhauser I, Flachenecker P, Heesen C
PATIENT EDUC COUNS. 2012;86(1):91-97.

New Developments in Paraneoplastic Neurological Diseases
Leypoldt F, Wandinger K, Voltz R
AKTUEL NEUROL. 2012;39(02):60-73.

Cortical atrophy in experimental autoimmune encephalomyelitis: in vivo imaging.
MacKenzie-Graham A, Rinek G, Avedisian A, Gold S, Frew A, Aguilar C, Lin D, Umeda E, Voskuhl R, Alger J
NEUROIMAGE. 2012;60(1):95-104.

[Depression and neurological diseases].
Piber D, Hinkelmann K, Gold S, Heesen C, Spitzer C, Endres M, Otte C
NERVENARZT. 2012;83(11):1423-1433.

Quantitative T2' imaging in patients with clinically isolated syndrome.
Reitz M, Inglese M, Fiehler J, Finsterbusch J, Holst B, Heesen C, Martin R, Schippling S
ACTA NEUROL SCAND. 2012;126(5):357-363.

Treatment of steroid-unresponsive optic neuritis with plasma exchange.
Roesner S, Appel R, Gbadamosi J, Martin R, Heesen C
ACTA NEUROL SCAND. 2012;126(2):103-108.

The XX sex chromosome complement in mice is associated with increased spontaneous lupus compared with XY.
Sasidhar M, Itoh N, Gold S, Lawson G, Voskuhl R
ANN RHEUM DIS. 2012;71(8):1418-1422.

TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis.
Schattling B, Steinbach K, Thies E, Kruse M, Menigoz A, Ufer F, Flockerzi V, Brück W, Pongs O, Vennekens R, Kneussel M, Freichel M, Merkler D, Friese M
NAT MED. 2012;18(12):1805-1811.

Childhood trauma in multiple sclerosis: a case-control study.
Spitzer C, Bouchain M, Winkler L, Wingenfeld K, Gold S, Grabe H, Barnow S, Otte C, Heesen C
PSYCHOSOM MED. 2012;74(3):312-318.

Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data.
Stellmann J, Neuhaus A, Herich L, Schippling S, Roeckel M, Daumer M, Martin R, Heesen C
PLOS ONE. 2012;7(11):50347.

Displacement chromatography as first separating step in online two-dimensional liquid chromatography coupled to mass spectrometry analysis of a complex protein sample--the proteome of neutrophils.
Trusch M, Tillack K, Kwiatkowski M, Bertsch A, Ahrends R, Kohlbacher O, Martin R, Sospedra M, Schlüter H
J CHROMATOGR A. 2012;1232:288-294.

Sex-related factors in multiple sclerosis susceptibility and progression.
Voskuhl R, Gold S
NAT REV NEUROL. 2012;8(5):255-263.

CD8-mediated inflammatory central nervous system disorders.
Willing A, Friese M
CURR OPIN NEUROL. 2012;25(3):316-321.

Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography
Brandt A, Oberwahrenbrock T, Ringelstein M, Young K, Tiede M, Hartung H, Martin R, Aktas O, Paul F, Schippling S
BRAIN. 2011;134(Pt 11):e193; author reply e194.

Biological outcome measurements for behavioral interventions in multiple sclerosis.
Fischer A, Heesen C, Gold S
Ther Adv Neurol Disord. 2011;4(4):217-229.

Investigating a training supporting Shared Decision Making (IT'S SDM 2011): study protocol for a randomized controlled trial.
Geiger F, Liethmann K, Hoffmann F, Paschedag J, Kasper J
TRIALS. 2011;12:232.

Endocrine and immune substrates of depressive symptoms and fatigue in multiple sclerosis patients with comorbid major depression.
Gold S, Krüger S, Ziegler K, Krieger T, Schulz K, Otte C, Heesen C
J NEUROL NEUROSUR PS. 2011;82(7):814-818.

Empowerment bei MS – Wie viel Selbstmanagement ist möglich?
Heesen C, Schäffler N, Kasper J, Simonow A, Köpke S
2011. Raum für Eigensinn - Ergebnisse eines Expertentreffens zur Patientenkompetenz. KVC-Verlag: 33-50.

Decisions on multiple sclerosis immunotherapy: new treatment complexities urge patient engagement.
Heesen C, Solari A, Giordano A, Kasper J, Köpke S
J NEUROL SCI. 2011;306(1-2):192-197.

Patients' and observers' perceptions of involvement differ. Validation study on inter-relating measures for shared decision making.
Kasper J, Heesen C, Köpke S, Fulcher G, Geiger F
PLOS ONE. 2011;6(10):26255.

Why not? - Communicating stochastic information by use of unsorted frequency pictograms - a randomised controlled trial.
Kasper J, Heesen C, Köpke S, Mühlhauser I, Lenz M
Psychosoc Med. 2011;8:8.

HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis.
Möller F, Poettgen J, Broemel F, Neuhaus A, Daumer M, Heesen C
MULT SCLER J. 2011;17(8):1002-1009.

Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.
Montalban X, Comi G, O'Connor P, Gold S, de Vera A, Eckert B, Kappos L
MULT SCLER J. 2011;17(11):1341-1350.

Accuracy of diagnostic tests in multiple sclerosis--a systematic review.
Schäffler N, Köpke S, Winkler L, Schippling S, Inglese M, Fischer K, Heesen C
ACTA NEUROL SCAND. 2011;124(3):151-164.

The giant extracellular matrix-binding protein of Staphylococcus epidermidis mediates biofilm accumulation and attachment to fibronectin.
Christner M, Franke G, Schommer N, Wendt U, Wegert K, Pehle P, Kroll G, Schulze C, Buck F, Mack D, Aepfelbacher M, Rohde H
MOL MICROBIOL. 2010;75(1):187-207.

[Multiple sclerosis].
Friese M
DEUT MED WOCHENSCHR. 2010;135(11):527-531.

Smaller cornu ammonis 2-3/dentate gyrus volumes and elevated cortisol in multiple sclerosis patients with depressive symptoms.
Gold S, Kern K, O'Connor M, Montag M, Kim A, Yoo Y, Giesser B, Sicotte N
BIOL PSYCHIAT. 2010;68(6):553-559.

Autoimmunerkrankungen
Heesen C, Gold S
2010. Psychoendokrinologie und Psychoimmunologie. Springer Verlag Berlin Heidelberg: 231-246.

Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists.
Heesen C, Kleiter I, Nguyen F, Schäffler N, Kasper J, Köpke S, Gaissmaier W
MULT SCLER J. 2010;16(12):1507-1512.

Bewegungstherapie bei Multipler Sklerose - supportiv, immunmodulierend oder regenerativ
Heesen C, Schulz K, Braumann M, Gold S, Daumer M
2010. Rehabilitation der Multiplen Sklerose. Hippocampus: 220-237.

N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes.
Irani S, Bera K, Waters P, Zuliani L, Maxwell S, Zandi Michael S, Friese M, Galea I, Kullmann D, Beeson D, Lang B, Bien C, Vincent A
BRAIN. 2010;133(6):1655-1667.

NCAM-induced neurite outgrowth depends on binding of calmodulin to NCAM and on nuclear import of NCAM and fak fragments.
Kleene R, Mzoughi M, Joshi G, Kalus I, Bormann U, Schulze C, Xiao M, Dityatev A, Schachner M
J NEUROSCI. 2010;30(32):10784-10798.

Functional role of the interaction between polysialic acid and extracellular histone H1.
Mishra B, von der Ohe M, Schulze C, Bian S, Makhina T, Loers G, Kleene R, Schachner M
J NEUROSCI. 2010;30(37):12400-12413.

Temporal and spatial dynamics of cerebral immune cell accumulation in stroke.
Gelderblom M, Leypoldt F, Steinbach K, Behrens D, Choe C, Siler D, Arumugam T, Orthey E, Gerloff C, Tolosa E, Magnus T
STROKE. 2009;40(5):1849-1857.

Suspected multiple sclerosis - what to do? Evaluation of a patient information leaflet.
Heesen C, Schäffler N, Kasper J, Mühlhauser I, Köpke S
MULT SCLER J. 2009;15(9):1103-1112.

T2' imaging indicates decreased tissue metabolism in frontal white matter of MS patients.
Holst B, Siemonsen S, Finsterbusch J, Bester M, Schippling S, Martin R, Fiehler J
MULT SCLER J. 2009;15(6):701-707.

[Evidence-based patient information: the example of immunotherapy for patients with multiple sclerosis]
Kasper J, Heesen C, Mühlhauser I
BUNDESGESUNDHEITSBLATT. 2009;52(1):77-85.

Patient education program to enhance decision autonomy in multiple sclerosis relapse management: a randomized-controlled trial.
Köpke S, Kasper J, Mühlhauser I, Nübling M, Heesen C
MULT SCLER J. 2009;15(1):96-104.

Modafinil effects in multiple sclerosis patients with fatigue.
Lange R, Volkmer M, Heesen C, Liepert J
J NEUROL. 2009;256(4):645-650.

Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report.
Leypoldt F, Münchau A, Moeller F, Bester M, Gerloff C, Heesen C
NEUROLOGY. 2009;72(11):1022-1024.

Early anisotropy changes in the corpus callosum of patients with optic neuritis.
Bester M, Heesen C, Schippling S, Martin R, Ding X, Holst B, Fiehler J
NEURORADIOLOGY. 2008;50(7):549-557.

Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable.
Heesen C, Böhm J, Reich C, Kasper J, Goebel M, Gold S
MULT SCLER J. 2008;14(7):988-991.

Spotlight on anti-CD25: daclizumab in MS.
Schippling S, Martin R
Int MS J. 2008;15(3):94-98.

Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system.
Friese M, Craner M, Etzensperger R, Vergo S, Wemmie J, Welsh M, Vincent A, Fugger L
NAT MED. 2007;13(12):1483-1489.

T cells and microglia as drivers of multiple sclerosis pathology.
Friese M, Fugger L
BRAIN. 2007;130(11):2755-2757.

Comparison of myelin, axon, lipid, and immunopathology in the central nervous system of differentially myelin-compromised mutant mice
Loers G, Aboul-Enein F, Bartsch U, Lassmann H, Schachner M
MOL CELL NEUROSCI. 2004;27(2):175-89.

Letzte Aktualisierung aus dem FIS: 17.08.2017 - 00:01 Uhr

Für weitere Informationen besuchen Sie unsere Website: